source
- Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startupVersant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
- Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concernsNovartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…BioSpace · 9h agoNegative readoutNegative